Results of a randomized phase III trial of mirabegron in patients with overactive bladder.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Urology

• Publication date

  2013-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.juro.2012.10.017PMID 23079373
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature

  2011cited by this paper
• Patient‐reported reasons for discontinuing overactive bladder medication

  2010cited by this paper
• Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.

  2010cited by this paper
• Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head‐to‐head placebo‐controlled trial

  2010cited by this paper
• Effects of CL316,243, a beta 3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat.

  2010cited by this paper
• Trospium chloride once‐daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials

  2009cited by this paper
• Persistence of antimuscarinic drug use

  2009cited by this paper
• Prospective pharmacologic therapies for the overactive bladder

  2009cited by this paper
• Clinical proof of concept study (blossom) shows novel beta 3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder

  2008cited by this paper
• The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.

  2008cited by this paper
• Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy

  2008cited by this paper
• Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double‐blind, placebo‐controlled, rising‐dose trial

  2008cited by this paper
• Persistence, Adherence, and Switch Rates Among Extended-Release and Immediate-Release Overactive Bladder Medications in a Regional Managed Care Plan

  2008cited by this paper
• Effect of (R)-2-(2-Aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} Acetanilide (YM178), a Novel Selective β3-Adrenoceptor Agonist, on Bladder Function

  2007cited by this paper
• Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder

  2005cited by this paper
• The responsiveness of the Overactive Bladder Questionnaire (OAB-q)

  2005cited by this paper
• Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

  2004cited by this paper
• Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder.

  2004cited by this paper
• Recent developments in the management of detrusor overactivity

  2003cited by this paper
• Role of β‐adrenoceptor subtypes in mediating relaxation of the pig bladder trigonal muscle in vitro

  2003cited by this paper
• Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

  2003cited by this paper
• Current pharmacotherapeutic strategies for overactive bladder

  2002cited by this paper
• β3-adrenoceptors in human detrusor muscle ☆

  2002cited by this paper
• Beta3-adrenoceptors in human detrusor muscle.

  2002cited by this paper
• MUSCARINIC RECEPTOR ANTAGONISTS IN THE TREATMENT OF OVERACTIVE BLADDER

  2000cited by this paper
• Effects of the (cid:1) 3-Adrenergic Receptor Agonist Disodium 5-[(2 R )-2-[[(2 R )-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL-316243) on Bladder Micturition Reflex in Spontaneously Hypertensive Rats

  year unknowncited by this paper

• Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials.

  2026cites this paper
• Is the Addition of CO2 Laser to β3-Adrenoceptor Agonist Mirabegron Effective in the Management of Overactive Bladder? Results of a Randomized Controlled Trial

  2025cites this paper
• Monotherapy with tolterodine or mirabegron is insufficient for ameliorating cyclophosphamide-induced bladder overactivity in rats.

  2025cites this paper
• Efficacy of Mirabegron and Propiverine Combination in the Treatment of Refractory Overactive Bladder

  2025cites this paper
• Antiarrhythmic effects of mirabegron on ventricular fibrillation in Langendorff‐perfused rabbit ventricles

  2025influential citation
• Predicting poor early voiding pattern after holep using maximum flow rate (Q-max) as an objective outcome

  2025cites this paper
• Impact of β3‐adrenergic receptor agonist on kidney cancer risk in patients with overactive bladder

  2025cites this paper
• Assessment of efficacy of mirabegron, solifenacin, tadalafil 5 mg and combination therapy in female patients with overactive bladder: a double blinded multicenter prospective placebo-controlled trial.

  2025cites this paper
• Therapeutic Potential of the β3-Adrenergic Receptor and Its Ligands in Cardiovascular Diseases

  2025cites this paper
• Impact of β3-adrenergic receptor agonist on tumor progression and metastasis in renal cell carcinoma models

  2025cites this paper
• From Research to Practice: The Role of Mirabegron in Managing Overactive Bladder

  2025cites this paper
• Comparative efficacy and adverse effects of β3-agonists and antimuscarinics in overactive bladder: a network and component network meta-analysis

  2025cites this paper
• Mirabegron for Cardiac Disease: A New Therapeutic Frontier.

  2025cites this paper
• Mirabegron Versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome-A Systematic Review.

  2024cites this paper
• GPCR-mediated regulation of beige adipocyte formation: implications for obesity and metabolic health.

  2024cites this paper
• An open-label, randomized, post-authorization study of mirabegron in Chinese participants with overactive bladder

  2024cites this paper
• The β3‐AR agonist BRL37344 ameliorates the main symptoms of X‐linked nephrogenic diabetes insipidus in the mouse model of the disease

  2024cites this paper
• Efficacy and Safety of Add-on Treatment with Mirabegron for Benign Prostatic Hyperplasia Patients with Persistent Storage Symptoms after Alpha‌- blocker therapy.

  2024cites this paper
• An individual participant meta‐analysis of mirabegron in multiple sclerosis and spinal cord injury

  2024cites this paper
• The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder

  2024cites this paper
• Mirabegron 50 mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II/III, randomized, double-blind, parallel-design, placebo-controlled, multicenter, and multinational trials

  2024cites this paper
• Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database

  2024cites this paper
• Reply: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial

  2024cites this paper
• 2024 Revised Dutch guidelines for urinary incontinence: Addressing clinical bottlenecks through a modular approach

  2024cites this paper
• Enhanced browning of adipose tissue by mirabegron-microspheres.

  2024cites this paper
• Urinary Incontinence Medications: Patient-Initiated Concerns in Primary Care.

  2024cites this paper
• Review of the Impact and Burden of Urinary Urgency on Adults with Overactive Bladder

  2024cites this paper
• Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders

  2023cites this paper
• Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7

  2023cites this paper
• Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms.

  2023cites this paper
• Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis

  2023cites this paper
• Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis

  2023cites this paper
• A Comparative Study on the effectiveness and Tolerability of Mirabegron and Antimuscarinics in the treatment of Overactive bladder

  2023cites this paper
• Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta‐analysis

  2023cites this paper
• Updates of Overactive Bladder in Pediatrics

  2023cites this paper
• Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis

  2023influential citation
• Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma

  2023cites this paper
• Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder

  2023cites this paper
• Topical estrogen therapy ameliorates bladder estrogen receptor β expression in female patients with overactive bladder.

  2023cites this paper
• A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder

  2023cites this paper
• Cost-Utility Analysis of Mirabegron Compared to Solifenacin in the Treatment of Overactive Bladder (OAB) in Iran

  2023cites this paper
• β3 Adrenergic Receptor Agonist Mirabegron Increases AQP2 and NKCC2 Urinary Excretion in OAB Patients: A Pleiotropic Effect of Interest for Patients with X-Linked Nephrogenic Diabetes Insipidus

  2023cites this paper
• Comparing efficacy and safety of mirabegron, tamsulosin, and solifenacin in ureteral stent-related symptoms: outcomes from a network meta-analysis

  2023cites this paper
• Treatment strategies for clear cell renal cell carcinoma: Past, present and future

  2023cites this paper
• Predicting Mirabegron Treatment Response in Patients with Overactive Bladder: A Post Hoc Analysis of Data from Clinical Trials.

  2023cites this paper
• Bayesian Borrowing Methods for Count Data: Analysis of Incontinence Episodes in Patients with Overactive Bladder

  2023influential citation
• Excavation of diagnostic biomarkers and construction of prognostic model for clear cell renal cell carcinoma based on urine proteomics

  2023cites this paper
• Harninkontinenz

  2023cites this paper
• Adrenoceptors in the Lower Urinary Tract.

  2023cites this paper
• Medical Therapy with Antimuscarinics and ß3-Agonists

  2022cites this paper
• Female Neurogenic Incontinence

  2022cites this paper
• Intracranial Metastatic Disease: Present Challenges, Future Opportunities

  2022cites this paper
• Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology

  2022cites this paper
• Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States

  2022cites this paper
• Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma

  2022cites this paper
• Evolving therapeutic landscape of advanced hepatocellular carcinoma

  2022cites this paper
• Mirabegron in the Management of Overactive Bladder Syndrome

  2022influential citation
• Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis

  2022cites this paper
• Vibegron for the treatment of overactive bladder: a comprehensive update

  2022cites this paper
• Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder

  2022cites this paper
• Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance database.

  2022cites this paper
• Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders-A cohort study.

  2022cites this paper
• Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

  2022cites this paper
• SUFU white paper on overactive bladder anticholinergic medications and dementia risk

  2022cites this paper
• Integration of Tumor Microenvironment in Patient-Derived Organoid Models Help Define Precision Medicine of Renal Cell Carcinoma

  2022cites this paper
• Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria

  2021cites this paper
• Case Report: Early 68Ga-PSMA-PET Metabolic Assessment and Response to Systemic Treatment for First-Line Metastatic Clear Cell Renal Cell Carcinoma; About Two Clinical Cases

  2021cites this paper
• First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials

  2021influential citation
• A Practical Approach for Primary Care Practitioners to Evaluate and Manage Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia.

  2021cites this paper
• Bladder Outlet Obstruction and Overactive Bladder in Males

  2021cites this paper
• Modern Radiation Therapy for the Management of Brain Metastases From Non-Small Cell Lung Cancer: Current Approaches and Future Directions

  2021cites this paper
• Beta 3 Adrenoreceptor Agonist for the Management of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia: A Systematic Review

  2021cites this paper
• Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis.

  2021cites this paper
• Initial Experience with Mirabegron for the Treatment of Neurogenic Lower Urinary Tract Dysfunction

  2021cites this paper
• Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison

  2021cites this paper
• The effect of Mirabegron and Duloxetine combination in mixed-type urinary incontinence treatment.

  2021cites this paper
• Integrated Transcriptomic Analysis Revealed Hub Genes and Pathways Involved in Sorafenib Resistance in Hepatocellular Carcinoma

  2021cites this paper
• Post-Operative Radiotherapy in Prostate Cancer: Is It Time for a Belt and Braces Approach?

  2021cites this paper
• Replication of Oncology Randomized Trial Results using Swedish Registry Real World‐Data: A Feasibility Study

  2021cites this paper
• Adverse events associated with mirabegron 50mg versus placebo: A systematic review and meta-analysis.

  2021cites this paper
• Salvage therapy for prostate cancer after radical prostatectomy

  2021cites this paper
• Sorafenib Versus Apatinib Both Combined Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Comparative Retrospective Study

  2021cites this paper
• High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma

  2021cites this paper
• Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study

  2021cites this paper
• Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial

  2021cites this paper
• Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study

  2021cites this paper
• Bladder Outlet Obstruction and Overactive Bladder in Females

  2021cites this paper
• The role of mirabegron in relieving double-J stent-related discomfort: a randomized controlled clinical trial

  2021cites this paper
• Development of an Aerobic Glycolysis Index for Predicting the Sorafenib Sensitivity and Prognosis of Hepatocellular Carcinoma

  2021cites this paper
• Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis

  2021influential citation
• The Urogynecology Section of the Polish Society of Gynecologists and Obstetricians guidelines on the management of non-neurogenic overactive bladder syndrome in women.

  2021cites this paper
• The efficacy and safety of mirabegron in treating ureteral stent‐related symptoms: A systematic review and meta‐analysis

  2021cites this paper
• Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma

  2021cites this paper
• A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder

  2021cites this paper
• Overactive-Bladder-Syndrom bei Frauen

  2021cites this paper
• Efficacy of salt reduction for managing overactive bladder symptoms: a prospective study in patients with excessive daily salt intake

  2021cites this paper
• ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma

  2021influential citation
• Management of Non-Neurogenic Male Lower Urinary Tract Symptoms ( LUTS ) , incl . Benign Prostatic Obstruction ( BPO ) EAU Guidelines on

  2021cites this paper
• Neuroinflammatory changes of the normal brain tissue in cured mice following combined radiation and anti-PD-1 blockade therapy for glioma

  2021cites this paper
• Trends in the kidney cancer mortality-to-incidence ratios according to health care expenditures of 56 countries

  2021cites this paper